Effects of Curcumin Analogues DMC and EF24 in Combination with the Cytokine TRAIL against Kidney Cancer

Gaspar, Verónica Ibáñez; McCaul, Jasmin; Cassidy, Hilary; Slattery, Craig; McMorrow, Tara

doi:10.3390/molecules26206302

Cited by 10 publications

(4 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, primary tumors frequently resist TRAIL-induced apoptosis [88]. Researchers tackled this by combining TRAIL with natural dimethoxycurcumin (DMC) or synthetic (EF24) analogues of CUR [89]. In renal adrenocarcinoma cells, TRAIL combined with DMC or EF24 significantly reduced cell viability (32.73% and 11.39%, respectively), and both analogues hindered cell migration [90].…”

Section: Renal Cell Carcinomamentioning

confidence: 99%

See 1 more Smart Citation

Anticarcinogenic Potency of EF24: An Overview of Its Pharmacokinetics, Efficacy, Mechanism of Action, and Nanoformulation for Drug Delivery

Sazdova,

Keremidarska-Markova,

Dimitrova

et al. 2023

Cancers

View full text Add to dashboard Cite

EF24, a synthetic monocarbonyl analog of curcumin, shows significant potential as an anticancer agent with both chemopreventive and chemotherapeutic properties. It exhibits rapid absorption, extensive tissue distribution, and efficient metabolism, ensuring optimal bioavailability and sustained exposure of the target tissues. The ability of EF24 to penetrate biological barriers and accumulate at tumor sites makes it advantageous for effective cancer treatment. Studies have demonstrated EF24’s remarkable efficacy against various cancers, including breast, lung, prostate, colon, and pancreatic cancer. The unique mechanism of action of EF24 involves modulation of the nuclear factor-kappa B (NF-κB) and nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathways, disrupting cancer-promoting inflammation and oxidative stress. EF24 inhibits tumor growth by inducing cell cycle arrest and apoptosis, mainly through inhibiting the NF-κB pathway and by regulating key genes by modulating microRNA (miRNA) expression or the proteasomal pathway. In summary, EF24 is a promising anticancer compound with a unique mechanism of action that makes it effective against various cancers. Its ability to enhance the effects of conventional therapies, coupled with improvements in drug delivery systems, could make it a valuable asset in cancer treatment. However, addressing its solubility and stability challenges will be crucial for its successful clinical application.

show abstract

Section: Renal Cell Carcinomamentioning

confidence: 99%

“…Elevated ROS production correlates with increased matrix metalloproteinase (MMP)-2 and -9 expression, promoting cell invasion and metastasis in colorectal cancer [89]. H 2 O 2 /TRAIL-induced death has been observed in TRAIL-resistant cells [91].…”

Section: Renal Cell Carcinomamentioning

confidence: 99%

Anticarcinogenic Potency of EF24: An Overview of Its Pharmacokinetics, Efficacy, Mechanism of Action, and Nanoformulation for Drug Delivery

Sazdova,

Keremidarska-Markova,

Dimitrova

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…DMC, one of the most important curcuminoids, possesses antitumor activities against various human cancer cells, including leukemia, glioma cells, baller cancer, cervical cancer carcinomas, and kidney tumors [ 120 , 121 , 122 , 123 , 124 ], and is an effective adjuvant. Although few investigations have been conducted to assess the effects of DMC on NSCLC, one study on A549 cells showed that DMC downregulates TP expression and represses the expression of ERCC1.…”

Section: The Impact Of Cur Analogs On Nsclcmentioning

confidence: 99%

Curcumin and Its Analogs in Non-Small Cell Lung Cancer Treatment: Challenges and Expectations

et al. 2022

View full text Add to dashboard Cite

Researchers have made crucial advances in understanding the pathogenesis and therapeutics of non-small cell lung cancer (NSCLC), improving our understanding of lung tumor biology and progression. Although the survival of NSCLC patients has improved due to chemoradiotherapy, targeted therapy, and immunotherapy, overall NSCLC recovery and survival rates remain low. Thus, there is an urgent need for the continued development of novel NSCLC drugs or combination therapies with less toxicity. Although the anticancer effectiveness of curcumin (Cur) and some Cur analogs has been reported in many studies, the results of clinical trials have been inconsistent. Therefore, in this review, we collected the latest related reports about the anti-NSCLC mechanisms of Cur, its analogs, and Cur in combination with other chemotherapeutic agents via the Pubmed database (accessed on 18 June 2022). Furthermore, we speculated on the interplay of Cur and various molecular targets relevant to NSCLC with discovery studio and collected clinical trials of Cur against NSCLC to clarify the role of Cur and its analogs in NSCLC treatment. Despite their challenges, Cur/Cur analogs may serve as promising therapeutic agents or adjuvants for lung carcinoma treatment.

show abstract

“…Research also shows that curcumin has a broad spectrum of antitumor activity, including kidney cancer, prostate cancer, ovarian cancer, and other malignant tumors. Curcumin can inhibit tumor cell survival, proliferation, invasion, migration, and induce apoptosis and autophagy [20][21][22].…”

Section: Introductionmentioning

confidence: 99%

Curcumin Inhibits Bladder Cancer by Inhibiting Invasion via AKT/MMP14 Pathway

Wang,

Xiao,

Zeng

2024

Discovery Medicine

View full text Add to dashboard Cite

Background: Bladder cancer is a malignant tumor of the urinary and reproductive tract that seriously threatens human health. It is urgent to develop new drugs for bladder cancer. This study aims to explore whether curcumin could inhibit bladder cancer and the potential mechanism. Methods: Firstly, network pharmacology was applied to explore the potential target of curcumin in bladder cancer. Among the potential target of curcumin on bladder cancer, the role of matrix metalloproteinase-14 (MMP14) was further explored by bioinformatic analysis and the expression of MMP14 was confirmed by immunohistochemistry staining. The effect of curcumin on bladder cancer was then studied using the cell counting kit-8 (CCK-8) assay, clone formation assay, apoptosis assay, and Transwell assay. Finally, AKT, MMP14, E-cadherin and N-cadherin were analyzed by Western blot assay to confirm whether curcumin could inhibit bladder cancer by inhibiting invasion via AKT/MMP14 pathway. Results: In the present study, we found that the target of curcumin for bladder cancer includes signal transducer and activator of transcription 3 (STAT3), AKT, cyclin A2 (CCNA2), epidermal growth factor receptor (EGFR), E1A binding protein p300 (EP300) and MMP14. MMP14 was highly expressed in bladder cancer than in normal tissues and was associated with a worse prognosis (p < 0.05). Curcumin could inhibit the proliferation and migration of bladder cancer cells (p < 0.05), while promoting cell apoptosis by inhibiting the AKT/MMP14 pathway (p < 0.05). Conclusion: Curcumin could inhibit bladder cancer by inhibiting invasion through the AKT/MMP14 pathway.

show abstract

Effects of Curcumin Analogues DMC and EF24 in Combination with the Cytokine TRAIL against Kidney Cancer

Cited by 10 publications

References 37 publications

Anticarcinogenic Potency of EF24: An Overview of Its Pharmacokinetics, Efficacy, Mechanism of Action, and Nanoformulation for Drug Delivery

Anticarcinogenic Potency of EF24: An Overview of Its Pharmacokinetics, Efficacy, Mechanism of Action, and Nanoformulation for Drug Delivery

Curcumin and Its Analogs in Non-Small Cell Lung Cancer Treatment: Challenges and Expectations

Curcumin Inhibits Bladder Cancer by Inhibiting Invasion via AKT/MMP14 Pathway

Contact Info

Product

Resources

About